At a glance
These weekly RSV vaccination coverage estimates for pregnant Women 18─49 years are based on electronic health record data from the Vaccine Safety Datalink.
RSV Vaccination Coverage, Pregnant Women
- These weekly RSV vaccination coverage estimates for pregnant women 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC's Immunization Safety Office and multiple integrated health care organizations.*
- The denominator includes those who reached at least 32 weeks gestation since September 22, 2023. Denominator may also include pregnant women who were past the recommended window of 32-36 weeks gestation prior to September 22, 2023. Pregnant women are not removed from the numerator or denominator when the pregnancy ends.
- The numerator includes those who have received an RSV vaccine as of the week ending date.
- Implementation timelines and availability of RSV vaccine differed across participating VSD sites; therefore, early coverage estimates may include women in the denominator who were not able to receive vaccination starting September 22, 2023, when the vaccine was first recommended. By November 25, 2023, all VSD sites were offering RSV vaccination to pregnant women.
- Figure 5. Percent of pregnant women ages 18-49 years vaccinated† with RSV vaccine overall and by race and ethnicity – Vaccine Safety Datalink
*Naleway AL, Crane B, Irving SA, Bachman D, Vesco KK, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Klein NP, McCarthy NL, McClure DL, Panagiotakopoulos L, Panozzo CA, Vazquez-Benitez G, Weintraub ES, Zerbo O, Kharbanda EO. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021 Jun 14;12:20420986211021233. doi: 10.1177/20420986211021233. PMID: 34178302; PMCID: PMC8207278.
†Vaccinations may have been administered outside the recommended window of 32-36 weeks gestation. Frequently Asked Questions About RSV Vaccine for Pregnant Women | CDC